Celecoxib Japan Observational Study for the Patients With Acute Pain

This study is to assess the safety and efficacy of celecoxib on the pain relief from acute pain.

Completed

Looking for future studies?

Key information

Conditions

Patients With Traumatic Pain, Post-surgical Pain and Tooth Extract Pain Acute Pain Neurologic Manifestations Pain Pain, Postoperative Pathologic Processes Pathological Conditions, Signs and Symptoms Postoperative Complications Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

Primary location

Chūbu, Japan

About this study

Patients with traumatic pain, post-surgical and tooth extract pain will be included in this study. Patients will receive Celecoxib for 2 weeks and the efficacy on pain relief and the safety will be evaluated.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with traumatic pain, post-surgical pain and tooth extract pain

Exclusion criteria

Hyperreactive to sulfonamide
Aspirin asthma patients
Peptidic ulcer patients
Serious liver disease patients
Serious kidney disease patients
Serious heart failure patients
End of pregnancy

Treatment and study plan

Celecoxib

Drug

oral

Other names: Celecox

Primary outcomes

Safety assessed by the incidence of adverse events and lab-tests

Time frame: For 2 weeks

Secondary outcomes

Overall pain improvement assessed by visual analogue scale (VAS)

Time frame: Baseline and week-2

Sponsors and collaborators

Lead sponsor

Astellas Pharma Inc

Industry

Registry information

Important dates

Study start: 2012
Primary completion: 2013
Study completion: 2013
First posted: Jun 12, 2013
Registry last updated: Sep 5, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed